Clinical and morphological peculiarities and treatment variants of syndrome of isolated proteinuria and/or hematuria in children of Kazakhstan

Aim of the study. To evaluate the pathological characteristics and results of treatment of children with isolated hematuria and/or proteinuria. In total 33 children who had isolated hematuria and/or proteinuria were examined. The most frequent pathological pattern was IgA-nephropathy – 16 (48,5%). In 15 (45,7%) of patients isolated hematuria and/or proteinuria were due to glomerular basement membrane abnormalities. In 2 (6%) patients mesangioprofilerative glomerulonephritis with IgM deposits was found. Four (12%) children (with IgA-nephropathy) with significant proteinuria (0,8 ± 0,3 g/day) and decreased glomerular filtration rate at the debut of the disease (less than 83 ± 10,1 ml/min) have received the maintenance immunosuppressive therapy with mycophenolate mofetil 500 mg/m²/day. Children with IgA-nephropathy manifested with isolated hematuria and/or proteinuria are in the group of increased risk of progression, especially proteinuria 0,5 g/day, decreased glomerular filtration rate, and prolonged maintenance immunosuppressive therapy combined with ACE inhibitors is effective. ACEi monotherapy is effective for both proteinuria decreasing and glomerular filtration rate normalization for all patients groups.

isolated hematuria and/or proteinuria, IgA-nephropathy, Alport’s syndrome, glomerular basement membrane abnormalities, mesangioproligerative glomerulonephritis with IgM deposits, AC inhibitors, mycophenolate mofetil, изолированная гематурия и/или протеинурия, IgA-нефропатия, синдром Альпорта, аномалии гломерулярной базальной мембраны, мезангиопролиферативный гломерулонефрит с депозитами IgМ, ингибиторы АПФ, мофетил микофенолат

1. Abbate M., Zoja C., Morigi M. et al. Transforming growth factor beta 1 is unregulated by podocytes in response to excess intraglomerular passage of protein: a central pathway in progressive glomerulosclerosis // Am. J. Pathol. 2002. Vol. 161. P. 2179–2199.

2. Appel G.B., Waldman M. The IgA nephropathy treatment dilemma. Mini Review // Kidney International. 2006. Vol. 69. P. 1939–1944.

3. Barratt J., Feehally J. Treatment of IgA nephropathy // Kidney International. 2006. Vol. 69. P. 1934–1938.

4. Buzza M., Wang Y.Y., Dagher H. et al. COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome // Kidney Int. 2001. Vol. 60. №2. P. 480–483.

5. Hogg R.J., Wyatt R.J. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy (ISRCTN6257616) // BMC Nephrol. 2004. Vol. 5. P. 3.

6. Kanno Y., Okada H., Saruta T. et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up // Clin. Nephrol. 2000. Vol. 54. P. 360–365.

7. Maes B.D., Oyen R., Claes K. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study // Kidney Int. 2004. Vol. 65. P. 1842–1849.

8. Pescucci C., Mari F., Longo I. et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene // Kidney Int. 2004. Vol. 65, №5. P. 1598–1603.

9. Praga M., Gutierrez E., Gonzalez E. et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial // J. Am. Soc. Nephrol. 2003. Vol. 14. P. 1578–1583.

10. Samuels J.A., Strippoli G.F., Craig J.C. et al. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials // Nephrology. Carlton. 2004. Vol. 9. P. 177–185.

11. Savige J., Rana K., Tonna S. et al. Thin basement membrane nephropathy // Kidney Int. 2003. Vol. 64. №4. P. 1169–1178.

12. Taal M., Brenner B. Reno protective benefits of RAS: From ACEI to angiotensin II antagonists // Kidney Int. 2000. Vol. 57. P. 1803–1817.

13. Tumlin J.A., Hennigar R.A. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy // Semin. Nephrol. 2004. Vol. 24. P. 256–268.